このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

InMed Pharmaceuticals 将来の成長

Future 基準チェック /16

InMed Pharmaceuticalsは収益が増加すると予測されています。

主要情報

n/a

収益成長率

n/a

EPS成長率

Pharmaceuticals 収益成長	27.6%
収益成長率	17.5%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	16 Feb 2024

今後の成長に関する最新情報

更新なし

Recent updates

InMed Pharmaceuticals GAAP EPS of -$33.17, revenue of $1.09M

Sep 26

InMed Pharma announces $6M private placement

Sep 09

InMed Pharma says phase 2 trial for skin disorder cannabinol cream can now include teens

Jul 25

InMed Pharmaceuticals gets non-compliance notice on Nasdaq minimum bid price requirement

Jul 13

InMed To Acquire Rare Cannabinoid Manufacturer BayMedica

Jul 02

InMed's INM-755 CBN cream did not introduce any delay in normal wound healing

Jan 08

業績と収益の成長予測

NasdaqCM:INM - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
6/30/2025	7	N/A	N/A	N/A	1
6/30/2024	5	N/A	N/A	N/A	1
3/31/2024	6	-6	-7	-7	N/A
12/31/2023	5	-6	-7	-6	N/A
9/30/2023	5	-7	-7	-7	N/A
6/30/2023	4	-8	-7	-7	N/A
3/31/2023	2	-15	-11	-11	N/A
12/31/2022	2	-17	-14	-14	N/A
9/30/2022	1	-19	-15	-15	N/A
6/30/2022	1	-19	-16	-16	N/A
3/31/2022	1	-14	-14	-14	N/A
12/31/2021	0	-14	-13	-13	N/A
9/30/2021	N/A	-12	-11	-11	N/A
6/30/2021	N/A	-10	-10	-10	N/A
3/31/2021	N/A	-9	-9	-9	N/A
12/31/2020	N/A	-7	-6	-6	N/A
9/30/2020	N/A	-8	-6	-6	N/A
6/30/2020	N/A	-9	-7	-7	N/A
3/31/2020	N/A	-10	-8	-8	N/A
12/31/2019	N/A	-11	-9	-8	N/A
9/30/2019	N/A	-10	-8	-8	N/A
6/30/2019	N/A	-10	-7	-7	N/A
3/31/2019	N/A	-9	-6	-6	N/A
12/31/2018	N/A	-8	-4	-4	N/A
9/30/2018	N/A	-7	-4	-4	N/A
6/30/2018	N/A	-6	-4	-4	N/A
3/31/2018	N/A	-6	-3	-3	N/A
12/31/2017	N/A	-5	N/A	-3	N/A
9/30/2017	N/A	-5	N/A	-3	N/A
6/30/2017	N/A	-3	N/A	-2	N/A
3/31/2017	N/A	-2	N/A	-2	N/A
12/31/2016	N/A	-2	N/A	-1	N/A
9/30/2016	N/A	-2	N/A	0	N/A
6/30/2016	N/A	-2	N/A	0	N/A
3/31/2016	N/A	-3	N/A	-1	N/A
12/31/2015	N/A	-3	N/A	-2	N/A
9/30/2015	N/A	-3	N/A	-2	N/A
6/30/2015	N/A	-3	N/A	-2	N/A
3/31/2015	N/A	-3	N/A	-1	N/A
12/31/2014	N/A	-2	N/A	-1	N/A
9/30/2014	N/A	-2	N/A	-1	N/A
6/30/2014	N/A	-1	N/A	-1	N/A
3/31/2014	N/A	0	N/A	0	N/A
12/31/2013	N/A	0	N/A	0	N/A
9/30/2013	N/A	0	N/A	0	N/A

アナリストによる今後の成長予測

収入対貯蓄率: INMの予測収益成長が貯蓄率 ( 2.4% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: INMの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: INMの収益が今後 3 年間で大幅に増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: INMの収益 ( 17.5% ) US市場 ( 8.5% ) よりも速いペースで成長すると予測されています。

高い収益成長: INMの収益 ( 17.5% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: INMの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

InMed Pharmaceuticals 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Recent updates

New major risk - Financial position

Third quarter 2024 earnings released: US$0.18 loss per share (vs US$0.60 loss in 3Q 2023)

InMed Pharmaceuticals Inc. Announces Additional Preclinical Data Demonstrating INM-901'S Positive Pharmacological Effects in the Potential Treatment of Alzheimer's Disease

Second quarter 2024 earnings released: US$0.18 loss per share (vs US$0.91 loss in 2Q 2023)

InMed Pharmaceuticals Inc. Announces Chief Financial Officer Changes, Effective February 20, 2024

Inmed Pharmaceuticals Inc. Announces the Launch of Inm-089

InMed Pharmaceuticals Inc. Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023

InMed Pharmaceuticals Inc. announced that it has received CAD 5.000002 million in funding

Inmed Pharmaceuticals Inc. Selects A Lead Alzheimer's Disease Drug Candidate, Named INM-901

InMed Pharmaceuticals Inc. announced that it expects to receive CAD 2.500001 million in funding

InMed Pharmaceuticals Inc. announced delayed annual 10-K filing

Full year 2023 earnings released: US$3.25 loss per share (vs US$33.17 loss in FY 2022)

InMed Pharmaceuticals Inc., Annual General Meeting, Dec 19, 2023

InMed Pharmaceuticals Inc. announced delayed 10-Q filing

InMed Pharmaceuticals Inc. Appoints Jonathan Tegge as Interim Chief Financial Officer

InMed Pharmaceuticals Inc. announced that it has received CAD 6.000011 million in funding

Inmed Pharmaceuticals Inc. Announces Promotion of Sarah Li to Controller and Principal Accounting Officer

Inmed Pharmaceuticals Inc. Provides Update on Management Changes

InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada Alliance Grant Funding

InMed Pharmaceuticals Inc., Annual General Meeting, Dec 15, 2022

InMed Pharmaceuticals GAAP EPS of -$33.17, revenue of $1.09M

InMed Pharmaceuticals Inc. to Report Fiscal Year 2022 Results on Sep 23, 2022

InMed Pharmaceuticals Inc. announced that it has received $6.000007 million in funding

InMed Pharmaceuticals Inc. announced that it expects to receive $6.000007 million in funding

InMed Pharma announces $6M private placement

InMed Pharmaceuticals Inc. Appoints Nicole Lemerond to Its Board of Directors

InMed Pharmaceuticals Inc. Provides an Update on Its Phase 2 Clinical Trial

InMed Pharma says phase 2 trial for skin disorder cannabinol cream can now include teens

InMed Pharmaceuticals Inc. Announces Michael Woudenberg Has Been Appointed Chief Operating Officer

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

InMed Pharmaceuticals gets non-compliance notice on Nasdaq minimum bid price requirement

InMed Pharmaceuticals Inc. Receives Written Notice from the Listing Qualifications Department Staff of the Nasdaq Capital Market

InMed Pharmaceuticals Inc. Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions

InMed Pharmaceuticals Inc. announced that it has received $1.499999 million in funding

InMed Pharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of $3.500002 million.

InMed Pharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of $4.25 million.

Inmed Pharmaceuticals Inc. Announces Appointment of Bryan Baldasare to Its Board of Directors Effective May 13, 2022

InMed Pharmaceuticals Inc. Cannabidivarin, Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector

InMed Pharmaceuticals Inc. Announces Board Changes

InMed Pharmaceuticals Inc. to Report Q2, 2022 Results on Feb 15, 2022

InMed Launches Cannabicitran (CBT), Expanding Its Rare Cannabinoid Portfolio for the Health and Wellness Sector

InMed Pharmaceuticals Inc. announced that it has received $12 million in funding

InMed To Acquire Rare Cannabinoid Manufacturer BayMedica

InMed Pharmaceuticals Inc. (NasdaqCM:INM) entered into a nonbinding letter of intent to acquire BayMedica Inc. for $4.7 million.

Inmed Pharmaceuticals Increases Cannabinoid Yield to 5 G/L with IntegraSyn in Advance of Commercial Scale Production

InMed Pharmaceuticals Announces Voluntary Delisting from TSX

InMed Pharmaceuticals Achieves 2G/L Cannabinoid Yield with Integrasyn

InMed Pharmaceuticals Inc. announced that it has received $4.4625 million in funding

New 90-day high: US$5.35

InMed Pharmaceuticals Inc. announced that it expects to receive $4.499998 million in funding

InMed Pharmaceuticals Inc. Announces Top-Line Results from Its 755-102-HV Phase 1 clinical trial

InMed's INM-755 CBN cream did not introduce any delay in normal wound healing

New 90-day low: US$3.07

InMed Pharmaceuticals Inc. Licenses MiDROPS Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoids

InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

New 90-day low: US$3.21

InMed Pharmaceuticals and BayMedica Announce Collaboration for Manufacturing and Testing of Novel Cannabinoid Therapeutics

Inmed Pharmaceuticals Inc's Common Stock Deleted from Other OTC

InMed Pharmaceuticals Inc. to Report Q1, 2021 Results on Nov 13, 2020

InMed Pharmaceuticals Inc. Announces Completion of Subject Treatments in Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘